Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Clinical Pharmacology and Therapeutics
|
March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.
Clinical Pharmacology and Therapeutics
|
October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2
Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.
Journal of Inherited Metabolic Disease
|
October 15, 2019
Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria
Lakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
The Lancet. Infectious Diseases
|
October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Saye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
Nature Communications
|
November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
I'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
Trials
|
July 27, 2021
AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter
Gareth O Griffiths, Richard FitzGerald, Thomas Jaki, et al.
The Journal of Antimicrobial Chemotherapy
|
August 27, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Saye H Khoo, Richard Fitzgerald, Thomas Fletcher, et al.
Annals of the Rheumatic Diseases
|
December 6, 2014
Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment
Lakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
The Journal of Clinical Investigation
|
July 15, 2025
Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer's disease models
Anusha R Pallapati, Funda Korkmaz, Satish Rojekar, et al.
The Lancet. Diabetes & Endocrinology
|
August 22, 2020
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial
Lakshminarayan R Ranganath, Eftychia Eirini Psarelli, Jean-Baptiste Arnoux, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Clinical Pharmacology and Therapeutics
|
March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.
Clinical Pharmacology and Therapeutics
|
October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2
Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.
Journal of Inherited Metabolic Disease
|
October 15, 2019
Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria
Lakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
The Lancet. Infectious Diseases
|
October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Saye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
Nature Communications
|
November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
I'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
Trials
|
July 27, 2021
AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter
Gareth O Griffiths, Richard FitzGerald, Thomas Jaki, et al.
The Journal of Antimicrobial Chemotherapy
|
August 27, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Saye H Khoo, Richard Fitzgerald, Thomas Fletcher, et al.
Annals of the Rheumatic Diseases
|
December 6, 2014
Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment
Lakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
The Journal of Clinical Investigation
|
July 15, 2025
Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer's disease models
Anusha R Pallapati, Funda Korkmaz, Satish Rojekar, et al.
The Lancet. Diabetes & Endocrinology
|
August 22, 2020
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial
Lakshminarayan R Ranganath, Eftychia Eirini Psarelli, Jean-Baptiste Arnoux, et al.
Page
of 6